All three patients with partial response (PR) were at dose level 2 and had translocation-related sarcomas (TRS; myxoid liposarcoma, synovial sarcoma, extraskeletal Ewing sarcoma in one patient each) with confirmation of fusion genes (EWS-CHOP1, SYT-SSX1, and EWS mutation, respectively). Here, SSX1 is linked to Ewing sarcoma.